Zobrazeno 1 - 10
of 165
pro vyhledávání: '"Nita L Seibel"'
Autor:
Keri Toner, Carl E. Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom, Jonathan W. Friedberg, Nita L. Seibel, Kara Kelly
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 921-926 (2023)
Abstract Lymphoma is one of the most common cancers in adolescents and young adults, but historically, this population has had lower clinical trial enrollment and improvements in overall survival as compared to other age populations. There are multip
Externí odkaz:
https://doaj.org/article/288e72642e4543a781aee5d684258469
Autor:
Steven G. DuBois, Mark D. Krailo, Julia Glade-Bender, Allen Buxton, Nadia Laack, R. Lor Randall, Helen X. Chen, Nita L. Seibel, Matthew Boron, Stephanie Terezakis, Christine Hill-Kayser, Andrea Hayes, Joel M. Reid, Lisa Teot, Dinesh Rakheja, Richard Womer, Carola Arndt, Stephen L. Lessnick, Brian D. Crompton, E. Anders Kolb, Heike Daldrup-Link, Eric Eutsler, Damon R. Reed, Katherine A. Janeway, Richard G. Gorlick
Publikováno v:
Journal of Clinical Oncology. 41:2098-2107
PURPOSE Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::161510daef43486d7607a1274091fcff
https://doi.org/10.1200/jco.22.01815
https://doi.org/10.1200/jco.22.01815
Autor:
D Williams, Parsons, Katherine A, Janeway, David R, Patton, Cynthia L, Winter, Brent, Coffey, P Mickey, Williams, Sinchita, Roy-Chowdhuri, Gregory J, Tsongalis, Mark, Routbort, Nilsa C, Ramirez, Lauren, Saguilig, Jin, Piao, Todd A, Alonzo, Stacey L, Berg, Elizabeth, Fox, Douglas S, Hawkins, Jeffrey S, Abrams, Margaret, Mooney, Naoko, Takebe, James V, Tricoli, Nita L, Seibel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(20)
PURPOSE The National Cancer Institute–Children's Oncology Group Pediatric MATCH trial aimed to facilitate evaluation of molecular-targeted therapies in biomarker-selected cohorts of childhood and young adult patients with cancer by screening tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3189532393c9b3c1d67a9f7fb23d5c9e
https://pubmed.ncbi.nlm.nih.gov/35353553
https://pubmed.ncbi.nlm.nih.gov/35353553
Publikováno v:
Cancer. 128:3843-3849
Participation of adolescents and young adults (AYAs) in oncology clinical trials is important to ensure adequate opportunities for AYA patients to contribute to, and benefit from, advances in cancer treatment.Accrual data for National Cancer Institut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6688421a62e854a31ed392a7af81775a
https://doi.org/10.1002/cncr.34402
https://doi.org/10.1002/cncr.34402
Autor:
Olive S. Eckstein, Carl E. Allen, P. Mickey Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo, Stacey L. Berg, Nilsa C. Ramirez, Alok Jaju, Joyce Mhlanga, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Katherine A. Janeway, Nita L. Seibel, D. Williams Parsons
Publikováno v:
Journal of Clinical Oncology. 40:2235-2245
PURPOSE The NCI-COG Pediatric MATCH trial assigns patients age 1-21 years with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies of molecularly targeted therapies on the basis of detection of predefined gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fefec09e4b88fe8840a88cf929d3fb0
https://doi.org/10.1200/jco.21.02840
https://doi.org/10.1200/jco.21.02840
Autor:
Susan N Chi, Joanna S Yi, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent D Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez, Alok Jaju, Joyce C Mhlanga, Elizabeth Fox, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, D Williams Parsons
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background NCI-COG Pediatric MATCH assigns patients aged 1-21 years with refractory solid tumors, brain tumors, lymphomas, and histiocytic disorders to phase II trials of molecularly targeted therapies based on detection of pre-defined genetic altera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::287b50580ea01adeaefb52fc91ae7354
https://doi.org/10.1093/jnci/djad085
https://doi.org/10.1093/jnci/djad085
Autor:
Jun J. Yang, William E. Evans, William L. Carroll, Chunliang Li, Wentao Yang, Nita L. Seibel, Hui Zhang, Charnise Goodings, Shuyu E, Deepa Bhojwani, Xujie Zhao, Heng Xu
Table S1 shows that downregulation of ARID5B led to more increases in LC50 of MTX and 6-MP than other antileukemic drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::747ac56ab8bdf9fc426a9dc0c95193d0
https://doi.org/10.1158/1078-0432.22473152.v1
https://doi.org/10.1158/1078-0432.22473152.v1
Autor:
Jun J. Yang, William E. Evans, William L. Carroll, Chunliang Li, Wentao Yang, Nita L. Seibel, Hui Zhang, Charnise Goodings, Shuyu E, Deepa Bhojwani, Xujie Zhao, Heng Xu
Figure S1 shows the knock-down effect of ARID5B with different shRNAs in Nalm6 cells; Figure S2 shows the correlation between MTX and 6-MP sensitivity with different levels of ARID5B knock-down in Nalm6 cells; Figure S3 shows that down-regulation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab5be458a4ed80c1281320f15fe2255
https://doi.org/10.1158/1078-0432.22473155.v1
https://doi.org/10.1158/1078-0432.22473155.v1
Autor:
Jun J. Yang, William E. Evans, William L. Carroll, Chunliang Li, Wentao Yang, Nita L. Seibel, Hui Zhang, Charnise Goodings, Shuyu E, Deepa Bhojwani, Xujie Zhao, Heng Xu
Purpose:Treatment outcomes for childhood acute lymphoblastic leukemia (ALL) have improved steadily, but a significant proportion of patients still experience relapse due to drug resistance, which is partly explained by inherited and/or somatic geneti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528773cd9550296b888818f53517a5d9
https://doi.org/10.1158/1078-0432.c.6528431
https://doi.org/10.1158/1078-0432.c.6528431
Autor:
Angela B. Mariotto, Ashley Wilder Smith, Nita L. Seibel, Elizabeth J. Siembida, Denise Riedel Lewis
Publikováno v:
Cancer. 127:4277-4286
BACKGROUND Five-year relative survival for adolescent and young adult (AYA) patients with cancer diagnosed at the ages of 15 to 39 years is 85%. Survival rates vary considerably according to the cancer type. The purpose of this study was to analyze l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4a381699e1379756d4b0a2ad4778ae0
https://doi.org/10.1002/cncr.33793
https://doi.org/10.1002/cncr.33793